CoChat
Sign Up
Cited by 138Cholesterol and Lipid MetabolismLipid metabolism and disordersLipoproteins and Cardiovascular Health

Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.

Open access
Ji, Z.S., Fazio, S., Mahley, R.W.·1994·Journal of Biological Chemistry
DOI 10.1016/s0021-9258(17)36849-7
Open this paper in CoChat — free account

Abstract

The initial step in the clearance of apolipoprotein (apo) E-enriched remnant lipoproteins from the plasma appears to be sequestration within the liver mediated by their binding to heparan sulfate proteoglycans (HSPG). The surface-bound remnants are believed to be internalized by their interaction with the low density lipoprotein (LDL) receptor-related protein or by the LDL receptor. Cholesterol-induced rabbit beta-very low density lipoproteins (beta-VLDL) enriched in human apoE3 display 4-5-fold enhanced binding to cultured cells. The present study attempts to determine whether recessive versus dominant type III hyperlipoproteinemia might be explained, at least in part, by a variable interaction of the mutant forms of apoE with the HSPG and impaired uptake. The beta-VLDL+apoE2(Arg158-->Cys), which is associated with recessive type III hyperlipoproteinemia, bound more poorly than beta-VLDL+apoE3 but still possessed significant enhanced binding (approximately 2-2.5-fold compared with beta-VLDL without added apoE) to HepG2 and McA-RH7777 cells. In comparison, beta-VLDL+apoE(Arg142-->Cys), beta-VLDL+apoE(Arg145-->Cys), and beta-VLDL+apoE-Leiden, which are associated with dominant type III hyperlipoproteinemia, bound more poorly. This same hierarchy of binding and uptake was determined by [14C]oleate incorporation into cholesteryl esters in LDL receptor-negative cells and by secretion of apoE3 and the variant apoE forms from McA-RH7777 cells. Furthermore, the enhanced binding of the apoE-enriched beta-VLDL was almost totally inhibited by heparinase treatment of the cells, and the basal binding activity was inhibited by 80-90% following addition of an LDL receptor antibody capable of blocking receptor-ligand interaction. The beta-VLDL enriched in apoE or apoE-dimyristoylphosphatidylcholine complexes bound to isolated HSPG from McA-RH7777 cells or the rat liver to a very similar degree. Likewise, the binding of beta-VLDL plus the various forms of apoE to the LDL receptor-related protein on ligand blots paralleled the results of other studies. In conclusion, all of the type III hyperlipoproteinemic apoE variants are defective in displaying enhanced binding to HSPG and in the cellular uptake initiated by HSPG. However, apoE2(Arg158-->Cys) displayed more activity than the variants associated with the dominant forms of type III hyperlipoproteinemia. The hierarchy of binding and uptake was as follows: apoE3 > apoE2(Arg158-->Cys) > apoE(Arg145-->Cys) > apoE(Arg142-->Cys) approximately apoE-Leiden (the latter two usually displaying very little, if any, enhanced binding and uptake). Thus, a correlation exists between the mode of expression of type III hyperlipoproteinemia and the binding and uptake of the specific apoE mutation.

Integrity signals

Registry

Crossref · 10.1016/s0021-9258(17)36849-7

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Ji, Z. S., Fazio, S., & Mahley, R. W.
Affiliations
Gladstone Institutes (US)
ORCID
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
1994-05
Volume
269
Issue
18
Pages
13421-13428
ISSN
0021-9258 (ISSN-L)
DOI
10.1016/s0021-9258(17)36849-7
OpenAlex
W1597396112
Cited by
138
References
40
Citations by year
2026: 3 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 1 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 3 · 2012: 3
FWCI
12.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (HL-41633, P01HL041633)
Topics
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords
heparan sulfate proteoglycans, type III hyperlipoproteinemia, beta-VLDL, LDL receptor, LDL receptor-related protein, hepatic uptake, APOE2, heparinase, lipoprotein binding
MeSH terms
Animals, Apolipoproteins E, Cholesterol Esters, Fibroblasts, Heparitin Sulfate, Heparan Sulfate, Humans, Hyperlipoproteinemias, Ligands, Lipoproteins, VLDL, Liver, Polysaccharide-Lyases, Protein Binding, Proteoglycans, Rabbits, Receptors, LDL, Tumor Cells, Cultured, Heparin Lyase, Heparan Sulfate Proteoglycans, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review